Denver– TriSalus Life Sciences, Inc. (Nasdaq: TLSI) announced a key leadership change with the appointment of David B. Patience as its new Chief Financial Officer, effective July 1, 2025. Patience will succeed James E. Young, who is stepping down from the role for personal reasons. During the transition, Dan Giordano, the company’s Vice President of Finance, will serve as acting CFO. Young will remain available to support the transition process.
TriSalus, a company focused on integrating innovative drug delivery systems with immunotherapeutic treatments for solid tumors, sees Patience’s arrival as a strategic move to support its next stage of growth. CEO Mary Szela welcomed the incoming CFO, noting his strong background in capital markets and operational execution. “David’s financial leadership will be invaluable as we continue to advance our mission and expand our reach in oncology,” she said. Szela also thanked Young for his service, wishing him success in his future endeavors.
Patience joins TriSalus from Accelerate Diagnostics, where he served as CFO since 2023. His previous experience includes roles in investment banking and equity research, with firms such as Morgan Stanley, Continental Advisors, and Nuveen Investments. He has led initiatives in strategic portfolio planning, mergers and acquisitions, and financial feasibility analysis across the healthcare sector. Patience holds a Bachelor of Science in Business Administration from the University of Colorado and an M.B.A. from the University of Chicago Booth School of Business.
The leadership transition comes as TriSalus continues to develop its platform combining pressure-enabled drug delivery technology with immunotherapy, aiming to enhance treatment outcomes for patients with liver and pancreatic tumors.
